ShA new study that will be presented on Wednesday at the European Breast Cancer Congress, in Milan, Italy, revealed that a drug against breast cancer could save more lives. Early use may provide more effective results.
This is pembrolizumab, brand Keytruda, which is currently used in more aggressive forms of the disease. According to the new study, it can bring benefits when used in the early stages, before and potentially after surgery.
Read also: Foods that can help reduce the risks of inflammation and cancer
According to The Guardian, the research has been ongoing for eight years in several countries and covers more than 1,200 patients. They were treated with pembrolizumab and chemotherapy before and after surgery.
About 24.3% of patients had no cancer cells after treatment. “This interesting study shows that adding pembrolizumab to chemotherapy before and after surgery may be more effective in eliminating cancer cells. In women with the disease it is more common,” explains Simon Vincent, one of those responsible for the study.
“Research found that pembrolizumab resulted in no detectable cancer cells in the breasts of more patients when treatment ended, although more research is needed to see if this translates into better survival rates.”
Read also: Colorectal cancer. “Early diagnosis can actually save lives”
Download our free app.
Consumer's Choice for the eighth consecutive year in online journalism and the 2024 Producer of the Year.
*Study by e Netsonda, November. And ten. Product of the Year 2023 – pt.com
Andrea Hargraves is a contributor to Brytfmonline.com, covering a broad range of topics including news, politics, business, technology, sports, entertainment, and lifestyle. She is committed to delivering clear, accurate, and reader-focused reporting that helps audiences stay informed about current events and emerging developments. Andrea’s work emphasizes useful information, balanced coverage, and stories that matter to everyday readers, making complex topics accessible and relevant to a wide audience.